Puzol-cel treatment for relapsed or refractory blood cancer
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study tracks how well Puzol-cel (a type of cell therapy) works for patients with B-cell acute lymphoblastic leukemia (a blood cancer) that has come back or stopped responding to previous treatments. The goal is to understand safety and effectiveness in real-world use in China.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia (blood cancer that has returned or stopped responding to treatment)
- Your cancer cells test positive for CD19 (a marker found on leukemia cells) confirmed by bone marrow testing
- You are being treated at a certified research center in China that Chongqing Precision Biotech has approved
- Your major organs (heart, lungs, liver, kidneys) are working essentially normally
- You test negative for hepatitis C, HIV, and syphilis
- You or your legal guardian can provide informed consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
This trial tests a new cell therapy (QH103) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses specially modified immune cells to find and kill cancer cells that have a protein called CD19 on their surface.
This trial tests a CAR-T cell therapy called Inaticabtagene Autoleucel (CNCT19) for people with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) who are in their first complete remission. It aims to see if this treatment can help prevent relapse without a stem cell transplant.
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
This trial tests a combination of targeted immunotherapy (a drug that helps your immune system fight cancer) plus low-dose chemotherapy for adults newly diagnosed with a specific type of blood cancer called Ph-negative B-ALL. The goal is to see if this approach can work better than standard treatments while being easier on your body.
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.